Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)
1.0000
+0.3700 (58.73%)
NASDAQ · Last Trade: Jun 17th, 2:19 PM EDT
Detailed Quote
Previous Close
0.6300
Open
1.250
Bid
0.9901
Ask
1.010
Day's Range
0.8417 - 1.260
52 Week Range
0.4519 - 7.200
Volume
50,355,137
Market Cap
44.78M
PE Ratio (TTM)
-0.2075
EPS (TTM)
-4.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
571,928
Chart
About Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)
Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer patients. The company specializes in the research and development of novel drug candidates that target specific epigenetic mechanisms to combat various forms of cancer. By harnessing the potential of these targeted therapies, Salarius aims to improve treatment outcomes and minimize side effects for patients. The company's approach emphasizes precision medicine, with a commitment to addressing unmet medical needs in oncology through robust scientific innovation and clinical trials. Read More
Power Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics.
Salarius Pharmaceuticals (NASDAQ: SLRX) shares are trading higher Monday after the company announced a merger agreement with Decoy Therapeutics, a privately held biopharmaceutical company.
